RATIO-TOPISALIC LOTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); SALICYLIC ACID

Beschikbaar vanaf:

TEVA CANADA LIMITED

ATC-code:

D07XC01

INN (Algemene Internationale Benaming):

BETAMETHASONE

Dosering:

0.5MG; 20MG

farmaceutische vorm:

LOTION

Samenstelling:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG; SALICYLIC ACID 20MG

Toedieningsweg:

TOPICAL

Eenheden in pakket:

30ML/60ML

Prescription-type:

Prescription

Therapeutisch gebied:

ANTI-INFLAMMATORY AGENTS

Product samenvatting:

Active ingredient group (AIG) number: 0215695003; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2013-02-22

Productkenmerken

_ _
_ratio-TOPISALIC Lotion (Betamethasone Dipropionate and Salicylic
Acid) _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RATIO-TOPISALIC
Betamethasone Dipropionate (0.5 mg / g as base)
and Salicylic Acid (20 mg / g)
LOTION
TOPICAL CORTICOSTEROID AND KERATOLYTIC
TEVA CANADA LIMITED
Date of Revision:
30 Novopharm Court
April 17, 2020
Toronto, Ontario,
Canada M1B 2K9
www.tevacanada.com
Submission Control No: 235690
_ _
_ratio-TOPISALIC Lotion (Betamethasone Dipropionate and Salicylic
Acid) _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
1
INDICATIONS
.................................................................................................................
3
1.1
Pediatrics
...................................................................................................................
3
1.2
Geriatrics
...................................................................................................................
3
2
CONTRAINDICATIONS
................................................................................................
3
3
DOSAGE AND ADMINISTRATION
............................................................................
3
3.1
Dosing Considerations
..............................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
.......................................................... 4
4
MISSED DOSE
.................................................................................................................
4
5
OVERDOSAGE
................................................................................................................
4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 4
7
WARNINGS AND PRECAUTIONS
..............................................